INFLEXION EVENT
Healthcare
Healthcare and Life Sciences sector is comprised of businesses which have high levels of IP and technological know-how, mission-driven teams, and potential to become international champions. The rapid pace of change in some areas of technology and molecular biology lends it to entrepreneurial teams and investors like Inflexion.
Sector spotlight: Healthcare
Portfolio
Filter by
CNX Therapeutics
Pharmaceuticals
In 2021 Inflexion acquired CNX Therapeutics, a European pharmaceutical company dedicated to the supply of essential medicines. The business was formed when Inflexion acquired Sunovion Pharmaceuticals Europe Limited. View case study
European LifeCare
Vaccination Services
In 2018 Inflexion invested in European LifeCare, Europe's largest independent provider of travel clinics and public vaccination programmes. View case study
HKI
Healthcare information services
In 2004 Inflexion acquired public health performance analytics business HKI in a £10m deal. The business was later sold in two parts for an overall return of 2.6x. View case study
ICS
Temporary staffing solutions
Temporary healthcare staffing business ICS chose to partner with Inflexion in 2008. It was sold 22 months later to Blackstone Group for an overall return on investment of 2.9x. View case study
Lintbells
Supplements for pets
In 2017, Inflexion invested in Lintbells, the UK’s leading producer of nutritional supplements for pets. View case study
Medivet
Veterinary services
In 2016, Inflexion provided minority funding to support the expansion of Medivet, a UK veterinary pet-care business. A successful partnership delivered strong acquisitive and organic growth, and Medivet was sold in 2021 to CVC Capital Partners. View case study
Pharmaspectra
Medical affairs data
In 2019, Inflexion invested in Pharmaspectra, a leading global provider of medical affairs data to the pharmaceutical and biotech industry. Inflexion exited the business in 2022. View case study
Phlexglobal
Clinical research documentation management
Inflexion backed the buyout of TMF services provider Phlexglobal in 2011, supporting its growth until it was sold to Bridgepoint Development Capital in 2014. View case study
Proteros
Drug discovery research platform
Proteros Biostructures GmbH is a leading Germany-based founder-led contract research organisation focused on early-stage drug discovery. View case study
Rosemont Pharmaceuticals
Liquid pharmaceuticals
In 2020 Inflexion acquired Rosemont Pharmaceuticals, the UK’s leading liquid pharmaceuticals business. The business was carved out of listed parent company, Perrigo. View case study
SteriPack
Medical device contract designer and manufacturer
SteriPack is a leading global contract manufacturer serving the medical device, pharmaceutical and diagnostic markets. Inflexion led the buyout of SteriPack in 2022. View case study
Upperton Pharma Solutions
Particle engineering for the pharmaceutical industry
In 2022, Inflexion made a substantial investment into Upperton Pharma Solutions, a UK based specialist contract development and manufacturing organisation which has expertise in particle engineering for the pharmaceutical industry. View case study
Village Vets
Veterinary services
Village Vets is the largest independent group of veterinary practices in the Republic of Ireland. Inflexion’s Enterprise Fund invested in the business in 2024 to support management’s ambitions to provide an enhanced offering to its customers through organic and acquisitive growth. View case study
Team
Ben Long
Partner
Ben is a Partner and head of the Healthcare sector at Inflexion. Read biography
Andrew Neville
Partner
Andrew is a Partner responsible for appraising and executing majority and minority investments as well as originating new mid-market opportunities, with a focus on the healthcare sector. Read biography
Christian Fellowes
Investment Director
Christian is an Investment Director on the Healthcare team and brings a combination of medical, transaction and entrepreneurial experience to Inflexion. Read biography
Rob Dagger
Investment Director
Rob is an Investment Director responsible for originating, evaluating and executing transactions. Read biography
Robin Senivassen
Investment Director
Robin is an Investment Director responsible for transaction execution and supporting the origination of investment opportunities in the lower mid-market. Read biography
Ravi Shah
Investment Director
Ravi is an Investment Director responsible for evaluating and executing transactions. Read biography
Sam McPhail
Investment Director
Sam is an Investment Director responsible for evaluating and executing transactions as well as supporting the origination of investment opportunities. Read biography
News, insights and events
Articles